Terms: = Leukemia AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP AND Clinical Outcome
4 results:
1. MicroRNA profiling of paediatric AML with
Leoncini PP; Vitullo P; Reddel S; Tocco V; Paganelli V; Stocchi F; Mariggiò E; Massa M; Nigita G; Veneziano D; Fadda P; Scarpa M; Pigazzi M; Bertaina A; Rota R; Pagliara D; Merli P
Oncol Rep; 2022 Dec; 48(6):. PubMed ID: 36321792
[TBL] [Abstract] [Full Text] [Related]
2. A clinical laboratory-developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia.
Ng SWK; Murphy T; King I; Zhang T; Mah M; Lu Z; Stickle N; Ibrahimova N; Arruda A; Mitchell A; Mai M; He R; Madala BS; Viswanatha DS; Dick JE; Chan S; Virtanen C; Minden MD; Mercer T; Stockley T; Wang JCY
Blood Adv; 2022 Feb; 6(3):1064-1073. PubMed ID: 34872104
[TBL] [Abstract] [Full Text] [Related]
3. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
Mill CP; Fiskus W; DiNardo CD; Birdwell C; Davis JA; Kadia TM; Takahashi K; Short N; Daver N; Ohanian M; Borthakur G; Kornblau SM; Green MR; Qi Y; Su X; Khoury JD; Bhalla KN
Blood; 2022 Feb; 139(6):907-921. PubMed ID: 34601571
[TBL] [Abstract] [Full Text] [Related]
4. RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.
Gust KM; Hofer MD; Perner SR; Kim R; Chinnaiyan AM; Varambally S; Moller P; Rinnab L; Rubin MA; Greiner J; Schmitt M; Kuefer R; Ringhoffer M
Neoplasia; 2009 Sep; 11(9):956-63. PubMed ID: 19724689
[TBL] [Abstract] [Full Text] [Related]
